preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder

conclusions this preliminary assessment suggests that duloxetine may be a medication of interest in the treatment of children with adhd. further controlled studies with larger samples are required to evaluate the efficacy of duloxetine in treatment of children with adhd. results ten children with a mean age of 8.40 ± 1.67 years terminated the trial. a significant reduction in cprs-r and its subscales was evident from week four of the study. in terms of side effects, duloxetine was generally safe and well tolerated. patients and methods in an open label clinical trial, 13 children aged 6 – 11 years diagnosed with adhd were prescribed 30 mg/day duloxetine once daily by oral administration for six weeks. conners parent rating scale-revised-short form (cprs-r-s) and the adhd rating scale were used to assess the efficacy of the treatment. objectives in this study, we investigated the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of children with attention-deficit hyperactivity disorder (adhd). background stimulants are first-line agents for the treatment of attention-deficit/hyperactivity disorder (adhd). despite the impressive track record of stimulants in the treatment of adhd, they fail in 25% of patients due to lack of efficacy or the emergence of unwanted side effects.